Skip to main content
Enclose phrases in quotes. Use a + to require a term in results and - to exclude terms.
Example: +water -Europe
Main navigation - Mobile
5. John Milligan, Gilead Sciences
Gilead's ex-CEO racked up $26M in pay, severance for 2018
Monday, March 18, 2019
Gilead CEO John Milligan racked up $26M in 2018 pay, on paper at least, while incoming chief Daniel O'Day is in line for a cool $30M this year.
Gilead's HIV portfolio soars, but can it make up for HCV losses?
Friday, October 26, 2018
Gilead's third-quarter results offered a glimmer of hope for continued growth—particularly in HIV—but Wall Street skeptics weren't convinced.
Celgene veteran Fouse top pick for Gilead CEO: analyst
Tuesday, July 31, 2018
RBC Capital Markets investors picked an oncology expert as their top candidate to replace Gilead CEO John Milligan.
Gilead's top execs Milligan and Martin stepping down
Wednesday, July 25, 2018
Gilead Sciences' two top executives, Chairman John C. Martin and CEO John Milligan, are leaving at the end of 2018.
Growth-stymied Gilead promotes dealmaker to top strategy post
Tuesday, June 5, 2018
Gilead's promotion of Andrew Dickinson, and a fresh licensing deal, could signal that Gilead's looking outside its own walls for growth opportunities.
With hep C still under fire, Gilead's bottoming out
Wednesday, May 2, 2018
Gilead may have some exciting prospects ahead, but for now, its cash-cow hepatitis C business is a big drag. The good news? It's a 'trough year.'
Gilead CEO Milligan pulls in 11% pay raise amid waning revenues
Tuesday, March 27, 2018
A host of challenges that drove Gilead's revenues down 14% last year didn’t stop its board from boosting the CEO’s pay package to $15.4 million.
How Kite got Gilead to boost its buyout price by 42%
Friday, September 8, 2017
Kite Pharma CEO Arie Belldegrun turned a single buyout bid into a $12 billion deal by capitalizing on suitor Gilead’s need to make a game-changing deal.
Gilead execs 'enamored' of Kite's CAR-T manufacturing
Friday, September 1, 2017
Kite Pharma's ability to handle the complex manufacturing of its CAR-T cancer treatment is one reason Gilead is paying $11.9 billion for the company.